Experimentally, navitoclax kills cells within a BAX/BAK-dependent manner and brings about regression of lymphoid tumors in xenograft models.In animal reports, navitoclax was observed to get a senolytic agent, inducing apoptosis in senescent, although not non-senescent cells.[4] Oral administration of ABT263 to either sublethally irradiated or norma